MedTrace Logo

Incentivized Smoking Cessation for Diabetics

NCT03527667 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-12-06

No results posted yet for this study

Summary

This pilot study aims to test the feasibility of providing incentives to patients with T2D contingent on remote biochemical verification using a smartphone carbon monoxide (CO) monitor. The investigators will use an ecological momentary assessment (EMA) smartphone application and CO sensor to monitor urges to smoke, stressors, smoking behaviors, and to validate continuous abstinence throughout the intervention. Two different contingency management structures will be explored to investigate the length of time incentives need to be offered.

Conditions

  • Smoking Cessation
  • Diabetes Mellitus, Type 2

Interventions

BEHAVIORAL

Financial incentives

Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • University of Strathclyde

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Sydney A Martinez, PhD · University of Oklahoma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-22
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03527667 on ClinicalTrials.gov